Key Drivers
- Strong liquidity
- High gross margin
- Thin operating profitability
AIAI Summary
Vericel has transitioned into a cash‑flowing commercial growth story where MACI volume/ASP-driven margin expansion—not pipeline binary outcomes—now dictates valuation, so investors should require several sequential quarters of accelerating MACI implant growth and clear operating‑margin improvement to justify current rich multiples while recognizing that MACI concentration and elevated SG&A/R&D spending create high execution risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •High gross margin
- •Thin operating profitability
VCEL has strong liquidity and high gross margins with positive free cash flow, but heavy operating expenses, low returns and a large accumulated deficit weaken profitability while extremely high market multiples imply premium growth expectations.
Price Behavior
Key Price Behavior Insights:
- •Below SMA
- •34–38.5 cap
- •Mean-reversion setup
VCEL is in a short-term downtrend: the last month SMA ~$34.46 vs. the 2026-03-20 close of $31.41 (~8–9% below), indicating bearish momentum with resistance at $34.0–$38.5 and support near $31.41 and $32.1–$33.0.
Sharp drop from around $38 in late
Sentiment & News
Key News Insights:
- •MACI growth
- •High margins
- •Investor sell-down
Vericel posted strong FY/ Q4 2025 results with 21% annual MACI revenue growth, doubled-quarterly margins and EPS in line with consensus, while a major investor cut its stake in early March.
The results reinforce Vericel's revenue and profitability momentum, likely supporting the stock near term despite the notable investor repositioning
Similar Companies in Healthcare
Other companies in the same sector with AI ratings